logo
Endocrine disruptors and kids: What they are and how to lower exposure

Endocrine disruptors and kids: What they are and how to lower exposure

Yahoo5 days ago
Pediatrician-mom tips for understanding endocrine disruptors and making simple swaps
You've probably heard the buzz about plastics and their potential risks, especially for children. But what exactly are these risks, and why are certain chemicals, known as endocrine disruptors, gaining attention? As a parent, it's natural to want to make the best choices for your family, but it can feel overwhelming to navigate the sea of information out there.
Here's what to know, where they're commonly found, and how to take small, practical steps that feel doable for your family.
What are endocrine disruptors?
Endocrine disruptors are chemicals that can interfere with the body's hormone systems. Hormones are like messengers that regulate everything from growth and metabolism to reproduction and mood. Endocrine disruptors can mimic or block these hormones when they enter the body. These disruptors can come from natural sources, like plants, or be synthetic and found in many everyday products.
Endocrine disruptors can be found in many of the products we use daily, making it difficult to avoid them completely. Over 1,000 endocrine disruptors have been identified, but here are some of the most common ones:
BPA (Bisphenol A): Often used in hard plastics like food containers, water bottles, and some older baby bottles and toys.
Phthalates and parabens: Found in plastic packaging, shampoos, lotions, and cosmetics.
Oxybenzone: Common in certain sunscreens.
Lavender and tea tree oils: Often found in skin care products.
Lead: Still present in older homes, vintage toys, and contaminated soil.
Soy-based products: Contain phytoestrogens, which are chemicals produced by plants that can mimic estrogen in the body.
Why it matters for babies and young kids
Endocrine disruptors interfere with the body's hormone systems by mimicking hormones like estrogen, blocking normal hormone activity, or altering hormone levels. Endocrine disruptors can affect how hormones are made, broken down, or stored, leading to imbalances. Additionally, they can change how sensitive the endocrine system is to various hormones, increasing or decreasing their effects. This is particularly concerning for pregnant women, infants, and young children who are more vulnerable to these hormonal disruptions during important stages of growth and development.
It's important to note that the research is ongoing; however, there is evidence that high exposure to endocrine disruptors can increase the risk of certain health issues. There is less evidence on what the actual safe levels are for people. As more research is available, the risks will become clearer.
During pregnancy, research suggests that endocrine disruptors can cross the placenta, leading to low birth weight, thyroid dysfunction, and neurological disorders. Repeated exposure to chemicals like BPA has been linked to early puberty, reproductive malformations, and infertility risks, as well as reproductive cancers. Endocrine disruptors are also associated with metabolic disorders, such as obesity and insulin resistance, and conditions like gynecomastia.
While these risks can seem alarming, it's important to acknowledge that most recommendations are aimed at reducing cumulative exposure rather than attempting to eliminate every source of endocrine disruptors.
Simple ways to reduce exposure
You don't need to eliminate every single source of endocrine disruptors. That's nearly impossible, and not the point. Instead, the goal is to reduce repeat exposure where it's easy and practical to do so.Avoid heating in plastic: Swap out plastic containers for glass or stainless steel, especially when heating food. If using plastic, make sure it's labeled 'BPA-free.'
Use BPA-free baby products: Choose infant bottles and toys labeled 'BPA-free,' or consider using glass bottles to reduce exposure.
Wash produce thoroughly: Pesticides can carry endocrine disruptors. Rinse fruits and vegetables well, or use a baking soda and water solution to minimize residues.Choose mineral sunscreens: Chemical sunscreens can contain oxybenzone, so consider mineral-based sunscreen made with zinc oxide or titanium dioxide.
Check labels for 'Phthalate-Free' or 'Paraben-Free': Opt for personal care products that do not contain these chemicals.
Be cautious with essential oils: Avoid the sue of topical formulations of tea tree and lavender oils in children. These can contain chemicals with estrogenic/androgenic properties, and repeated use of these oils has been linked to breast growth in prepubertal girls and boys.Limit plastic toys: especially older or hand-me-down plastic toys, as they may contain higher levels of harmful chemicals.
Reduce lead exposure: If you live in an older home, test for lead paint and make sure that any peeling paint is addressed.
Choose flame-retardant-free items: if possible, avoid products treated with flame retardants, which can also act as endocrine disruptors.
Keeping a balanced perspective
Focus on reducing repeated exposure in key areas. Remember, the 'dose makes the poison.' Overexposure is when problems are likely to occur, not from occasional contact with things like receipts or plastic water bottles.
It's easy to get swept up in fear, especially with the constant stream of new research on potential health risks. But balance is key. Make mindful choices that fit your family's lifestyle and needs, and don't feel pressured to overhaul everything all at once.
Want a calm, clear explanation of endocrine disruptors and which swaps actually matter most? Watch this PedsDocTalk YouTube video for more practical, pediatrician-backed tips.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DermaRite recalls antiseptic soaps and topical lotion due to infection risk
DermaRite recalls antiseptic soaps and topical lotion due to infection risk

Yahoo

time14 minutes ago

  • Yahoo

DermaRite recalls antiseptic soaps and topical lotion due to infection risk

A U.S. company that makes health care products is recalling four over-the-counter skin cleansers and an anti-itch lotion it says could lead to "serious and life-threatening infections." New Jersey-based DermaRite Industries announced on Friday that it was voluntarily recalling the health care products due to the fact that they may cause a microbial contamination known as Burkholderia cepecia, which may result in adverse reactions, particularly in immunocompromised individuals. In a company statement, DermaRite said the contaminated products "may be used by immunosuppressed individuals or by people who are attending to these individuals." The recall notice was also shared by the U.S. Food and Drug Administration. Symptoms for Burkholderia Cepecia Complex can range from fever and fatigue to serious respiratory infections, according to the Centers for Disease Control and Prevention. "In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis," the company said in its notice. According to its website, DermaRite creates wound care products, cleansers, moisturizers, hand soaps and other items for patients and caregivers operating in health care settings. DermaRite said it has not received any reports of adverse events related to this recall. Reached for comment, the company referred CBS MoneyWatch back to its statement. The items included in the recall include DermaKleen, DermaSarra, KleenFoam and PeriGiene — all of which serve slightly different health care purposes. DermaKleen, for example, is a antimicrobial hand cleanser, while DermaSarra offers relief from poison ivy, insect bites, and other skin irritants. DermaRite said it has reached out to its distributors and customers by e-mail and advised them "to immediately examine available inventory and destroy all affected products in accordance with each facility's process." The company said consumers who have used the products should contact their physician or health care provider if they have experienced any issues possibly related to use of the products. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Trump says he's placing D.C. police under federal control, deploying National Guard Jamie Lee Curtis: The 60 Minutes Interview Solve the daily Crossword

Proposed deal would bring former Prospect exec back to distressed hospitals
Proposed deal would bring former Prospect exec back to distressed hospitals

Yahoo

time18 minutes ago

  • Yahoo

Proposed deal would bring former Prospect exec back to distressed hospitals

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Nor Healthcare Systems Corp. appears poised to buy Prospect Medical Holding's California hospital portfolio out of bankruptcy, according to documents filed to a Texas bankruptcy court last week. The company was named the stalking horse bidder for the California assets, meaning Nor will set a floor price for the hospitals should an auction occur. Nor Healthcare was registered in Nevada just three months ago. The company lists no board of directors, general partners or trustees in its initial business application. However, it does name a director: Prospect veteran Michael Sarian. Sarian served as SVP of Prospect's hospital operations between 2005 and 2012. It could be a competitive auction. California is Prospect's core market, and attorneys told the court this month they have 'multiple active bidders' for the facilites. Should an auction go forward, an outcome will be decided by the end of the month, with a final sales hearing scheduled for Aug. 28. Dive Insight: Debt-ridden Prospect has sought to sell multiple facilities and opted to close others since filing for bankruptcy in January following years of financial difficulties. Each time, Prospect told the court it needed to act fast to divest in the face of mounting liquidity pressures. Critics say Prospect's to blame for its own cash problems and lack of interested buyers. Lawmakers in Pennsylvania and Connecticut say the health system ran its facilities into the ground by prioritizing profits over investments in patient care. California hospitals were meant to be safe from a fire sale. Prospect CEO Von Crockett entered the restructuring process intent on keeping the California market intact. However, six hospitals are now up for grabs, including Bellflower Behavioral Health Hospital, Los Angeles Community Hospital, Norwalk Community Hospital, Southern California Hospital at Culver City, Southern California Hospital at Hollywood and Van Nuys Behavioral Health Hospital. Prospect did not respond to requests for comment about possible sale terms for its California portfolio, including a purchase price. If Nor emerges as the buyer, it will be a homecoming of sorts for Sarian. Prospect purchased its first four California hospitals from Alta Hospitals System in 2007. Sarian sat at the head, serving as CEO of Alta and SVP of hospital operations for Prospect for approximately seven years, according to his LinkedIn profile and securities filings. Sarian's tenure coincides with the beginning of private equity firm Leonard Green & Partner's ownership of Prospect, which spanned 2010 to 2021. A bipartisan Senate investigation released earlier this year found that as early as 2010 Prospect began siphoning millions of dollars toward dividends and fees to benefit Leonard Green & Partners while hospital quality declined. After leaving Prospect in 2012, Sarian served as president of hospital operations at Prime Healthcare, managing operations for 45 hospitals across 15 states, before launching hospital turnaround firm Healthcare Systems of America and affiliate American Healthcare Systems. There, Sarian built a portfolio mostly by buying hospitals out of bankruptcy, including North Carolina-based Randolph Health in 2021 and eight hospitals formerly run by Steward Health Care last year. But American Healthcare Systems has had financial struggles of its own, according to a report from the Wall Street Journal. The health system has reportedly fallen behind on vendor payments at some of its facilities and, in other cases, failed to pay doctors on time. At one hospital, payment delays caused vendors to stop shipping critical medical supplies, including dialysis products, according to the report. Both Prime and HSA, where Sarian has worked, have done business with Prospect's long-time landlord, real estate investment trust Medical Properties Trust. Some familiarity could be a plus for helping Nor broker the California deal, because the stalking horse bid agreement stipulates that whomever takes over Prospect's California hospitals will enter into lease agreement with MPT. Such leases are often contentious. Lawmakers and academics have argued that sale leaseback transactions between hospitals and real estate investment trusts benefit investors by giving them quick access to cash but ultimately harm health systems by saddling them with unaffordable rent payments. HSA, Prospect, MPT and Nor did not respond to requests for comment on this article. Recommended Reading Prospect Medical Systems lays off 125 Sign in to access your portfolio

Heartflow's IPO raises $364M
Heartflow's IPO raises $364M

Yahoo

time18 minutes ago

  • Yahoo

Heartflow's IPO raises $364M

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Heartflow's initial public offering grossed $364.2 million after the volume and price of the shares sold exceeded the original expectations. The company listed last week and completed the sale of the overallotment on Monday, adding almost $50 million through the sale of additional shares. Heartflow's stock rose in its first two days on public markets, closing at almost $30 on Monday. The company priced its IPO at $19 a share. Dive Insight: Heartflow has developed software for making 3D heart models from coronary computed tomography angiography scans. In a clinical trial, the company linked its lead product, Heartflow FFRCT Analysis, to a 78% improvement in identifying patients in need of revascularization. Heartflow was aiming to sell 12.5 million shares for between $15 and $17 each when it set its IPO range early this month. At the midpoint of the range, the company would have raised $200 million before fees under the original plan. By the time Heartflow finalized the terms last week, the company had agreed to sell 16.7 million shares for $19 each. The changes increased the initial gross IPO amount to $316.7 million. Heartflow raised a further $47.5 million when underwriters took up their options to buy an additional 2.5 million shares in the overallotment. The company estimates net proceeds after fees will be $333.2 million. Heartflow's first two days on public markets provided further evidence of investor enthusiasm. The stock closed at $28.75 on Friday. After peaking and troughing during Monday's session, Heartflow closed up at just below $30. The closing price on Monday was almost 58% higher than the IPO price. The offering extends a recent uptick in IPO activity. Caris Life Sciences priced its IPO at $21 in June, having originally set a range of $16 to $18, and the precision medicine company's stock closed above $30 on Monday. Carlsmed hit the middle of its expected $14 to $16 range, raising more than $100 million to advance its spine platform, but its share price had slipped to $13 by market close on Monday. Recommended Reading Heartflow prices IPO, aiming to net about $180M

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store